This study aims to investigate the associations between LASS2 and cisplatin resistance in bladder cancer stem cells (BCSCs) and uncover the underlying molecular mechanisms, ultimately evaluating the role of LASS2 as a chemosensitizing target for bladder cancer. The gene discussed is CERS2; the disease is urinary bladder cancer.